What is Orforglipron and what is it used for?

Orforglipron is a treatment related to weight management. Hi-Doctor does not prescribe it today, but our licensed doctors can review your case and propose weight management alternatives with robust clinical evidence and EU regulatory approval.

Why does Hi-Doctor not prescribe Orforglipron?

Our doctors only prescribe treatments with robust clinical evidence, an EU-approved indication and a reviewed safety profile. Orforglipron is not on that list today — it may be investigational, not approved, or outside the scope of what we handle via telemedicine.

What alternatives can I consider within weight management?

Our doctors review your history and propose the most appropriate treatment among those authorised in the EU for weight management. The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health remains a €35 one-off consultation. If your case is not eligible, the applicable fee is refunded.

How would my weight management consultation work?

You fill in an online medical questionnaire (~4 min). An EU-licensed doctor reviews it and replies in less than 4 hours on average via the private chat in your account. If eligible, they issue a prescription electronic prescription valid in any EU pharmacy.

Can I get a consultation for Orforglipron from Palma de Mallorca?

Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Palma de Mallorca you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; in Spain it is dispensed directly from the prescription QR.

Who is a candidate for a medical weight-management programme?

Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.

What is the private electronic prescription and why is it valid across the EU?

The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

How does Hi-Doctor work step by step?

1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.

How much does it cost and what does the price include?

The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation — acne, rosacea, melasma, ageing skin — is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.

Orforglipron pack shot — a prescription medicine an EU-licensed doctor can prescribe online after a Hi-Doctor consultation in Palma de Mallorca.

Orforglipron · Palma de Mallorca

Orforglipron in Palma de Mallorca: what you should know.

NOT AVAILABLE IN THE EUOrforglipron has no EU marketing authorisation for this use.

We don't prescribe it today, but our doctors can review your case and propose an equivalent weight management treatment with EU approval and clinical evidence.

Review my weight management case

€25/month (billed €25 every 28 days)Full refund if a review is not approved

IN PLAIN TERMS

What Orforglipron is, and how to get treatment

Orforglipron is a weight-management tablet made by Eli Lilly. It is a pill version of the same idea behind the GLP-1 injections: it acts on the brain's appetite signals so you feel full sooner and eat less. It was approved in the United States on 1 April 2026 under the brand name Foundayo. It does not have a marketing authorisation in the European Union, so a doctor in the EU cannot prescribe it and you cannot get it from an EU pharmacy.

Orforglipron has no EU marketing authorisation for this use. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.

Can I get it?

Not for this use. Orforglipron has no EU authorisation for it, so it cannot be prescribed or dispensed here for that purpose.

Why buying it online is risky

What can I take instead?

Semaglutide is approved in the EU, has published peer-reviewed trial results, and can be prescribed today if a doctor decides it suits you.

Read about Semaglutide

What do the studies show?

Every trial behind Orforglipron is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.

Jump to the studies

Local consultation facts

Can I get Orforglipron in Palma de Mallorca?

Not through Hi-Doctor. Hi-Doctor does not prescribe Orforglipron. People in Palma de Mallorca, Spain, can request an online consultation for Weight loss with a licensed EU doctor, who may recommend an available option when clinically appropriate. If approved, the electronic prescription arrives as a QR code that can be dispensed directly in Spain.

Availability

Hi-Doctor does not prescribe Orforglipron. The links below show options in Weight loss that our doctors can assess.

Country: Spain
Language of service: Spanish and English
Prescription turnaround: In less than 4 hours on average, only if the doctor approves
Honoured locally: QR electronic prescription, dispensed directly in Spain

How the EU prescription works where you are: In Spain, an approved prescription arrives electronically with a QR code for direct dispensing.

A once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.

Daily tablets

€25/month

You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.

WHAT IT COSTS

One plan, reviewed by a doctor.

Weight loss

ONGOING PLAN

€25/month

Billed €25 every 28 days · cancel anytime

28-day treatment cycle

For ongoing treatment and doctor-reviewed renewals.

Renewals reviewed by your doctor

Start consultation

Full refund if a review is not approved

WHAT'S INCLUDED

First consultation included
Renewals reviewed by your doctor
Ongoing care with your doctor
Cancel anytime

Full refund if a review is not approved

If a review is not approved, we refund that period's €25 fee and cancel the plan.

Read the refund terms

Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.

VERIFIED EVIDENCE

Orforglipron: evidence and regulatory guide.

WHAT IT IS

How it works

A once-daily tablet that copies the effect of GLP-1, a natural gut hormone that tells the brain you have eaten enough, so hunger and food intake go down.

GLP-1

DEVELOPMENT STAGE

Not marketed in the EU

Trial register1 registered trials

Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.

Registered trials for Orforglipron
TRIAL / NCT	POPULATION	PARTICIPANTS	STATUS	READOUT / COMPLETION
ATTAIN-1NCT05869903	Adults with obesity, or overweight with at least one weight-related condition, without type 2 diabetes	3,127	Read out	2025-09-16

What the studies reported

Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.

Peer-reviewed

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. doi:10.1056/NEJMoa2511774 (PMID 40960239)

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. doi:10.1056/NEJMoa2511774 (PMID 40960239)
DOSE OR GROUP	MEAN WEIGHT CHANGE	WEEKS
6 mg daily	−7.5% body weight (95% CI −8.2 to −6.8)	72
12 mg daily	−8.4% body weight (95% CI −9.1 to −7.7)	72
36 mg daily	−11.2% body weight (95% CI −12.0 to −10.4)	72
Placebo	−2.1% body weight (95% CI −2.8 to −1.4)	72

ATTAIN-1 compared orforglipron only against placebo over 72 weeks; there is no head-to-head trial against the medicines authorised for weight management in the EU, and no long-term cardiovascular outcome data have been published.

Sources

Last reviewed 2026-07-27

NAMED SAFETY SIGNALS

What has been reported with Orforglipron.

Nausea

Reported by 28.9% (6 mg), 35.9% (12 mg) and 33.7% (36 mg) of participants in ATTAIN-1, versus 10.4% on placebo.

Constipation

Reported by 21.7% (6 mg), 29.8% (12 mg) and 25.4% (36 mg), versus 9.3% on placebo.

Diarrhoea

Reported by 21.0% (6 mg), 22.8% (12 mg) and 23.1% (36 mg), versus 9.6% on placebo.

Vomiting

Reported by 13.0% (6 mg), 21.4% (12 mg) and 24.0% (36 mg), versus 3.5% on placebo.

Stopping treatment because of side effects

5.3% (6 mg), 7.9% (12 mg) and 10.3% (36 mg) stopped orforglipron because of an adverse event, versus 2.7% on placebo.

UNAPPROVED PRODUCTS ONLINE

Why buying Orforglipron online is not a shortcut.

No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.

Check the EU common logo

A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.

How the EU common logo works

FREQUENTLY ASKED QUESTIONS